Primary central nervous system lymphoma

References

• Gavrilovic IT, Abrey LE. Diagnosis and treatment of primary central nervous system lymphoma. Curr. Oncol. Rep. 7, 47–54 (2005).
   Google Scholar
• Olson JE, Janney CA, Rao RD et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95, 1504–1510 (2002).
   PubMed Web of Science ®Google Scholar
• Kadan-Lottick NS, Skluzacek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95, 193–202 (2002).
   PubMed Web of Science ®Google Scholar
• Raizer JJ, DeAngelis LM. Primary central nervous system lymphoma. In: Textbook of Uncommon Cancer Second Edition. Raghavan ML, Brecher DH, Johnson NJ, Meropol PL, Thigpen JT (Eds). John Wiley and Sons, Chichester, UK, 323–333 (1999).
   Google Scholar
• Brink NS, Sharvell Y, Howard MR, Fox JD, Harrison MJ, Miller RF. Detection of Epstein-Barr virus and Kaposi’s sarcoma-associated herpesvirus DNA in CSF from persons infected with HIV who had neurological disease. J. Neurol. Neurosurg. Psychiatry 65(2), 191–195 (1998).
   PubMedGoogle Scholar
• Guterman KS, Hair LS, Morgello S. Epstein-Barr virus and AIDS-related primary central nervous system lymphoma. Viral detection by immunohistochemistry, RNA in situ hybridization, and polymerase chain reaction. Clin. Neuropathol. 15(2), 79–86 (1996).
   Google Scholar
• Montesinos-Rongen M, Besleaga R, Heinsohn S et al. Absence of simian virus 40 DNA sequences in primary central nervous system lymphoma in HIV-negative patients. Virchows Arch. 444, 436–438 (2004).
   PubMed Web of Science ®Google Scholar
• Corboy J, Garl P, Kleinschmidt-DeMasters BK. Human herpesvirus 8 DNA in CNS lymphomas from patients with and without AIDS. Neurology 50(2), 335–340 (1998).
   PubMed Web of Science ®Google Scholar
• Itoyama T, Sadamori N, Tsutsami K et al. Primary central nervous system lymphomas. Immunophenotypic, virologic, and cytogenetic findings of three patients without immune deficiencies. Cancer 73(2), 455–463 (1994).
   PubMed Web of Science ®Google Scholar
• Weber T, Weber RG, Kaulich K et al. Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol. 10(1), 73–84 (2000).
   Google Scholar
• Nakamura M, Kishi M, Sakaki T et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res. 6, 737–741 (2003).
   Google Scholar
• Boonstra R, Koning A, Mastik M, van den Berg A, Poppema S. Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q. Virchows Archiv. 443(2), 164–169 (2003).
   Google Scholar
• Braaten KM, Betensky RA, de Levai L et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin. Cancer Res. 9, 1063–1069 (2003).
   PubMed Web of Science ®Google Scholar
• Chang CC, Kampalath B, Schultz C et al. Expression of p53, c-myc, or bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch. Pathol. Lab. Med. 127, 208–212 (2003).
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri AJM, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann. Oncol. 8, 227–234 (1997).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Camilleri-Broet S, Soussain C. Recent advances in primary CNS lymphoma. Curr. Opin. Oncol. 16, 601–606 (2004).
   Google Scholar
• Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int. J. Rad. Oncol. Biol. Phys. 41(3), 615–620 (1998).
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J. Clin. Oncol. 21(2), 266–272 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin’s lymphoma of the brain: can high-dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. J. Rad. Oncol. Biol. Phys. 23(1), 9–17 (1992).
   PubMed Web of Science ®Google Scholar
• Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature. J. Neurosurg. 65(5), 600–607 (1986).
   PubMed Web of Science ®Google Scholar
• Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63(5), 939–947 (1989).
   PubMed Web of Science ®Google Scholar
• Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology 59(10), 1557–1562 (2002).
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J. Clin. Oncol. 16(3), 859–863 (1998).
   PubMed Web of Science ®Google Scholar
• Blay JY, Conroy T, Chevreau C et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J. Clin. Oncol. 16(3), 864–871 (1998).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 10(4), 635–643 (1992).
   PubMed Web of Science ®Google Scholar
• Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE. Cognitive functions in survivors of primary CNS lymphoma. Neurology 62, 548–555 (2004).
   PubMed Web of Science ®Google Scholar
• Lachance DH, Brizel DM, Gockerman JP et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 44(9), 1721–1727 (1994).
   PubMed Web of Science ®Google Scholar
• O’Neill BP, O’Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy? Int. J. Rad. Oncol. Biol. Phys. 33(3), 663–673 (1995).
   PubMed Web of Science ®Google Scholar
• Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Hotleman K. High-dose methotrexate for non-AIDS primary nervous system lymphoma. Report of 13 cases. J. Neurosurg. 70(2), 190–194 (1989).
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J. Neurosurgery 81(2), 188–195 (1994).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, DeAngeles LM. Treatment for Primary CNS lymphoma: the next step. J. Clin. Oncol. 18(17), 3144–3150 (2000).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma. Radiation Therapy Oncology Group Study 93-10. J. Clin. Oncol. 20(24), 4643–4648 (2002).
   Google Scholar
• Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J. Clin. Oncol. 21(24), 4483–4488 (2003).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Guerra E, Regazzi M et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br. J. Cancer 90(2), 353–358 (2004).
   PubMed Web of Science ®Google Scholar
• Kraemer D, Fortin D, Doolittle N, Neuwelt E. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 48(5), 1033–1038 (2001).
   PubMed Web of Science ®Google Scholar
• O’Brien P, Roos D, Pratt G et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J. Clin. Oncol. 18(3), 519–526 (2000).
   PubMed Web of Science ®Google Scholar
• Bleyer WA. Neurologic sequellae of methotrexate and ionizing radiation: a new classification. Cancer Treat. Rep. 65(Suppl. 1), 89–98 (1981).
   PubMedGoogle Scholar
• Wen PY, Ramkrishna N, Fisher D. Neurologic complications of lymphoma therapy. In: Lymphoma of the Central Nervous System. Batchelor T (Ed). Butterworth-Heinemann, Amsterdam, Boston 149–180 (2004).
   Google Scholar
• Peterson K, Rosenblum MK, Powers JM, Alvord E, Walker RW, Posner JB. Effect of brain irradiation on demyelinating lesions. Neurology 43(10), 2105–2112 (1993).
   Google Scholar
• Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 62(3), 451–456 (2004).
   PubMed Web of Science ®Google Scholar
• Harder H, Holtel H, Bromberg JEC et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62(4), 544–547 (2004).
   PubMed Web of Science ®Google Scholar
• Thiessen B, DeAngeles LM. Hydrocephalus in radiation leukoencephalopathy: results of ventriculoperitoneal shunting. Arch. Neurol. 55(5), 705–710 (1998).
   PubMedGoogle Scholar
• Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J. Clin. Oncol. 16(7), 2522–2527 (1998).
   PubMed Web of Science ®Google Scholar
• Rapp S, Rosdhal R, D’Agostino R et al. Improving cognitive functioning in brain irradiated patients: a phase 2 trial of an acetylcholinesterase inhibitor (donepezil). Neuro-oncol. 6(4), 357 (2004).
   Google Scholar
• Pels H, Schmidt-Wolf JG, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J. Clin. Oncol. 21(24), 4489–4495 (2003).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Tailandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J. Clin. Oncol. 21(14), 2726–2731 (2003).
   PubMed Web of Science ®Google Scholar
• Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology (46)6, 1757–1759 (1996).
   Google Scholar
• Freilich RJ, Delattre JY, Monjour A, DeAngeles LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46(2), 435–439 (1998).
   Google Scholar
• Doolittle ND, Miner ME, Hall WA et al. Safety and effacacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood–brain barrier for treatment of patients with malignant brain tumors. Cancer 88(3), 637–647 (2000).
   PubMed Web of Science ®Google Scholar
• McAllister LD, Doolittle ND, Guastadiegni PE et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46(1), 51–60 (2000).
   PubMed Web of Science ®Google Scholar
• Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant. 18(5), 1021–1023 (1996).
   PubMed Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Clin. Oncol. 19(3), 742–749 (2001).
   PubMed Web of Science ®Google Scholar
• Cheng T, Forsyth P, Chaudhry A et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant. 31(8), 679–685 (2003).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Moskowitz CH, Mason WP et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly-diagnosed primary CNS lymhoma: an intent to treat analysis. J. Clin. Oncol. 21(22), 4151–4156 (2003).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Brugger W, Bamberg M, Kuker W, Dichgans J, Weller M. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54(8), 1707–1708 (2000).
   PubMed Web of Science ®Google Scholar
• Reni M, Mason W, Zaja F et al. Salvage chemothrapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Euro. J. Cancer 40(11), 1682–1688 (2004).
   Google Scholar
• Fischer L, Thiel E, Klasen HA, Kirchen H, Jahnke K, Korfel A. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 62(10), 1885–1887 (2004).
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F. Salvage treatment with etoposide (VP-16), ifosfamide, and cytarabine (ara-C) for patients with recurrent primary central nervous system lymphoma. Euro. J. Haematol. 70(4), 219–224 (2003).
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Chakravarti A, Finkelstein DM et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J. Clin. Oncol. 23(7), 1507–1513 (2005).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD 20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92(6), 1927–1932 (1998).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825–2833 (1998).
   PubMed Web of Science ®Google Scholar
• Raizer JJ, DeAngelis LM, Schlutz MJ, Zelenta AE, Abrey LE. Activity of rituximab in primary central nervous system lymphoma PCNSL. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 642).
   Google Scholar
• Pels H, Schultz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J. Neuro-oncol. 59(3), 213–216 (2002).
   PubMed Web of Science ®Google Scholar
• Schultz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89, 753–754 (2004).
   Google Scholar
• Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101(1), 139–145 (2004).
   PubMed Web of Science ®Google Scholar
• Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63(5), 901–903 (2004).
   PubMed Web of Science ®Google Scholar
• Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br. J. Haematol. 126, 202–208 (2004).
   Google Scholar
• Valluri S, Moorthy RS, Khan A, Rao NA. Combination treatment of intraocular lymphoma. Retina 15(2), 125–129 (1995).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW. High-dose methotrexate for intraocular lymphoma. Clin. Cancer Res. 9(2), 711–715 (2003).
   PubMed Web of Science ®Google Scholar
• Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch. Ophthalmol. 115(9), 1152–1156 (1997).
   PubMed Web of Science ®Google Scholar
• Baumgartner JF, Rachlin JR, Beckstead JH et al. Primary central nervous lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J. Neurosurg. 73(2), 206–211 (1990).
   PubMed Web of Science ®Google Scholar
• Kaufmann T, Nisce LZ, Coleman M. A comparison of survival of patients treated for AIDS-related central nervous system lymphoma with and without tissue diagnosis. Int. J. Rad. Oncol. Biol. Phys. 36(2), 429–432 (1996).
   Google Scholar
• Ling SM, Roach M III, Larson DA, Wara WM. Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco. Cancer 73(10), 2570–2582 (1994).
   PubMed Web of Science ®Google Scholar
• Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 17(12), 1787–1793 (2003).
   PubMed Web of Science ®Google Scholar
• Aboulafia D. Interleukin-2, gangiclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clin. Infect. Dis. 34, 1660–1662 (2002).
   Google Scholar
• Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS 11(14), 1725–1730 (1997).
   PubMed Web of Science ®Google Scholar